Neoplastic Meningitis

ABSTRACT

Neoplastic meningitis is a common problem in neuro-oncology, occurring in ∼5% of all patients with cancer. Notwithstanding frequent focal signs and symptoms, neoplastic meningitis is a disease affecting the entire neuraxis; therefore, staging and treatment must encompass all cerebrospinal fluid (CSF) compartments. Central nervous system staging of neoplastic meningitis includes contrast-enhanced cranial computerized tomography or magnetic resonance imaging, contrast-enhanced spine magnetic resonance imaging, or computerized tomographic myelography and radionuclide CSF flow study (FS). Treatment of neoplastic meningitis includes involved-field radiotherapy of bulky or symptomatic disease sites and intra-CSF drug therapy. The inclusion of concomitant systemic therapy may benefit patients with neoplastic meningitis and may obviate the need for intra-CSF chemotherapy. At present, intra-CSF drug therapy is confined to three chemotherapeutic agents (i.e., methotrexate, cytosine arabinoside, and thio-triethylenephosphoramide) administered by a variety of schedules either by intralumbar or intraventricular drug delivery. Although treatment of neoplastic meningitis is palliative with an expected median patient survival of 2 to 6 months, it often affords stabilization and protection from further neurological deterioration.

KEYWORDS

Neoplastic meningitis - leptomeningeal metastases

REFERENCES

• 1 Shapiro W R, Posner J B, Ushio Y et al.. Treatment of meningeal neoplasms.  Cancer Treat Rep. 1977;  61 733-743
• 2 Nugent J L, Bunn Jr P A, Matthews M J et al.. CNS metastases in small cell bronchogenic carcinoma: increasing frequency and changing pattern with lengthening survival.  Cancer. 1979;  44 1885-1893
• 3 Kaplan J G, DeSouza T G, Farkash A et al.. Leptomeningeal metastases: comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias.  J Neurooncol. 1990;  9 225-229
• 4 Siegal T, Lossos A, Pfeffer M R. Leptomeningeal metastases: analysis of 31 patients with sustained off-therapy response following combined-modality therapy.  Neurology. 1994;  44 1463-1469
• 5 Chamberlain M C. Carcinomatous meningitis.  Arch Neurol. 1997;  54 16-17
• 6 Glass J P, Melamed M, Chernik N L et al.. Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology.  Neurology. 1979;  29 1369-1375
• 7 Wasserstrom W R, Glass J P, Posner J B. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients.  Cancer. 1982;  49 759-772
• 8 Little J R, Dale A J, Okazaki H. Meningeal carcinomatosis. Clinical manifestations.  Arch Neurol. 1974;  30 138-143
• 9 Rosen S T, Aisner J, Makuch R W et al.. Carcinomatous leptomeningitis in small cell lung cancer: a clinicopathologic review of the National Cancer Institute experience.  Medicine (Baltimore). 1982;  61 45-53
• 10 Am M H, Al Sarraf M, Baker L H et al.. Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival.  Cancer. 1978;  42 660-668
• 11 Yap H Y, Yap B S, Tashima C K et al.. Meningeal carcinomatosis in breast cancer.  Cancer. 1978;  42 283-286
• 12 van Oostenbrugge R J, Twijnstra A. Presenting features and value of diagnostic procedures in leptomeningeal metastases.  Neurology. 1999;  53 382-385
• 13 Balm M, Hammack J. Leptomeningeal carcinomatosis. Presenting features and prognostic factors.  Arch Neurol. 1996;  53 626-632
• 14 Sorensen S C, Eagan R T, Scott M. Meningeal carcinomatosis in patients with primary breast or lung cancer.  Mayo Clin Proc. 1984;  59 91-94
• 15 Gonzalez-Vitale J C, Garcia-Bunuel R. Meningeal carcinomatosis.  Cancer. 1976;  37 2906-2911
• 16 Grossman S A, Krabak M J. Leptomeningeal carcinomatosis.  Cancer Treat Rev. 1999;  25 103-119
• 17 Chamberlain M C. Radioisotope CSF flow studies in leptomeningeal metastases.  J Neurooncol. 1998;  38 135-140
• 18 Boyle R, Thomas M, Adams J H. Diffuse involvement of the leptomeninges by tumour-a clinical and pathological study of 63 cases.  Postgrad Med J. 1980;  56 149-158
• 19 Wolfgang G, Marcus D, Ulrike S. Leptomeningeal carcinomatosis; clinical syndrome in different primaries.  J Neurooncol. 1998;  38 103-110
• 20 Chamberlain M C, Kormanik P R. Carcinomatous meningitis secondary to breast cancer: predictors of response to combined modality therapy.  J Neurooncol. 1997;  35 55-64
• 21 Kolmel H W. Cytology of neoplastic meningosis.  J Neurooncol. 1998;  38 121-125
• 22 Murray J J, Greco F A, Wolff S N et al.. Neoplastic meningitis. Marked variations of cerebrospinal fluid composition in the absence of extradural block.  Am J Med. 1983;  75 289-294
• 23 Rogers L R, Duchesneau P M, Nunez C et al.. Comparison of cisternal and lumbar CSF examination in leptomeningeal metastasis.  Neurology. 1992;  42 1239-1241
• 24 Chamberlain M C, Kormanik P A, Glantz M J. A comparison between ventricular and lumbar cerebrospinal fluid cytology in adult patients with leptomeningeal metastases.  Neuro-oncol. 2001;  3 42-45
• 25 Glantz M J, Cole B F, Glantz L K et al.. Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results.  Cancer. 1998;  82 733-739
• 26 DeAngelis L M. Current diagnosis and treatment of leptomeningeal metastasis.  J Neurooncol. 1998;  38 245-252
• 27 Wasserstrom W R, Schwartz M K, Fleisher M et al.. Cerebrospinal fluid biochemical markers in central nervous system tumors: a review.  Ann Clin Lab Sci. 1981;  11 239-251
• 28 Van Zanten A P, Twijnstra A, Hart A A et al.. Cerebrospinal fluid lactate dehydrogenase activities in patients with central nervous system metastases.  Clin Chim Acta. 1986;  161 259-268
• 29 Klee G G, Tallman R D, Goellner J R et al.. Elevation of carcinoembryonic antigen in cerebrospinal fluid among patients with meningeal carcinomatosis.  Mayo Clin Proc. 1986;  61 9-13
• 30 Twijnstra A, van Zanten A P, Hart A A et al.. Serial lumbar and ventricle cerebrospinal fluid lactate dehydrogenase activities in patients with leptomeningeal metastases from solid and haematological tumours.  J Neurol Neurosurg Psychiatry. 1987;  50 313-320
• 31 Stockhammer G, Poewe W, Burgstaller S et al.. Vascular endothelial growth factor in CSF: a biological marker for carcinomatous meningitis.  Neurology. 2000;  54 1670-1676
• 32 Chamberlain M C. Cytologically negative carcinomatous meningitis: usefulness of CSF biochemical markers.  Neurology. 1998;  50 1173-1175
• 33 Garson J A, Coakham H B, Kemshead J T et al.. The role of monoclonal antibodies in brain tumour diagnosis and cerebrospinal fluid (CSF) cytology.  J Neurooncol. 1985;  3 165-171
• 34 Hovestadt A, Henzen-Logmans S C, Vecht C J. Immunohistochemical analysis of the cerebrospinal fluid for carcinomatous and lymphomatous leptomeningitis.  Br J Cancer. 1990;  62 653-654
• 35 Boogerd W, Vroom T M, van Heerde P et al.. CSF cytology versus immunocytochemistry in meningeal carcinomatosis.  J Neurol Neurosurg Psychiatry. 1988;  51 142-145
• 36 Van Oostenbrugge R J, Hopman A H, Ramaekers F C et al.. In situ hybridization: a possible diagnostic aid in leptomeningeal metastasis.  J Neurooncol. 1998;  38 127-133
• 37 Cibas E S, Malkin M G, Posner J B et al.. Detection of DNA abnormalities by flow cytometry in cells from cerebrospinal fluid.  Am J Clin Pathol. 1987;  88 570-577
• 38 Biesterfeld S, Bernhard B, Bamborschke S et al.. DNA single cell cytometry in lymphocytic pleocytosis of the cerebrospinal fluid.  Acta Neuropathol (Berl). 1993;  86 428-432
• 39 Van Oostenbrugge R J, Hopman A H, Arends J W et al.. The value of interphase cytogenetics in cytology for the diagnosis of leptomeningeal metastases.  Neurology. 1998;  51 906-908
• 40 Rhodes C H, Glantz M J, Glantz L et al.. A comparison of polymerase chain reaction examination of cerebrospinal fluid and conventional cytology in the diagnosis of lymphomatous meningitis.  Cancer. 1996;  77 543-548
• 41 Cheng T M, O'Neill B P, Scheithauer B W et al.. Chronic meningitis: the role of meningeal or cortical biopsy.  Neurosurgery. 1994;  34 590-595
• 42 Chamberlain M C, Sandy A D, Press G A. Leptomeningeal metastasis: a comparison of gadolinium-enhanced MR and contrast-enhanced CT of the brain.  Neurology. 1990;  40 435-438
• 43 Schumacher M, Orszagh M. Imaging techniques in neoplastic meningiosis.  J Neurooncol. 1998;  38 111-120
• 44 Sze G, Soletsky S, Bronen R et al.. MR imaging of the cranial meninges with emphasis on contrast enhancement and meningeal carcinomatosis.  AJR Am J Roentgenol. 1989;  153 1039-1049
• 45 Schuknecht B, Huber P, Buller B et al.. Spinal leptomeningeal neoplastic disease. Evaluation by MR, myelography and CT myelography.  Eur Neurol. 1992;  32 11-16
• 46 Chamberlain M C. Comparative spine imaging in leptomeningeal metastases.  J Neurooncol. 1995;  23 233-238
• 47 Freilich R J, Krol G, DeAngelis L M. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis.  Ann Neurol. 1995;  38 51-57
• 48 Mittl Jr R L, Yousem D M. Frequency of unexplained meningeal enhancement in the brain after lumbar puncture.  AJNR Am J Neuroradiol. 1994;  15 633-638
• 49 Glantz M J, Hall W A, Cole B F et al.. Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status.  Cancer. 1995;  75 2919-2931
• 50 Trump D L, Grossman S A, Thompson G et al.. CSF infections complicating the management of neoplastic meningitis. Clinical features and results of therapy.  Arch Intern Med. 1982;  142 583-586
• 51 Chamberlain M C, Kormanik P A. Prognostic significance of 111indium-DTPA CSF flow studies in leptomeningeal metastases.  Neurology. 1996;  46 1674-1677
• 52 Mason W P, Yeh S D, DeAngelis L M. 111Indium-diethylenetriamine pentaacetic acid cerebrospinal fluid flow studies predict distribution of intrathecally administered chemotherapy and outcome in patients with leptomeningeal metastases.  Neurology. 1998;  50 438-444
• 53 Chamberlain M C, Corey-Bloom J. Leptomeningeal metastases: 111indium-DTPA CSF flow studies.  Neurology. 1991;  41 1765-1769
• 54 Chamberlain M C, Kormanik P, Jaeckle K A et al.. 111Indium-diethylenetriamine pentaacetic acid CSF flow studies predict distribution of intrathecally administered chemotherapy and outcome in patients with leptomeningeal metastases.  Neurology. 1999;  52 216-217
• 55 Hildebrand J. Prophylaxis and treatment of leptomeningeal carcinomatosis in solid tumors of adulthood.  J Neurooncol. 1998;  38 193-198
• 56 Chamberlain M C, Kormanik P A. Prognostic significance of coexistent bulky metastatic central nervous system disease in patients with leptomeningeal metastases.  Arch Neurol. 1997;  54 1364-1368
• 57 Chamberlain M C. Neoplastic meningitis-related encephalopathy: prognostic significance.  Neurology. 2003;  60 A17-A18
• 58 Shapiro W R, Young D F, Mehta B M. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections.  N Engl J Med. 1975;  293 161-166
• 59 Berweiler U, Krone A, Tonn J C. Reservoir systems for intraventricular chemotherapy.  J Neurooncol. 1998;  38 141-143
• 60 Sandberg D I, Bilsky M H, Souweidane M M et al.. Ommaya reservoirs for the treatment of leptomeningeal metastases.  Neurosurgery. 2000;  47 49-54
• 61 Sause W T, Crowley J, Eyre H J et al.. Whole brain irradiation and intrathecal methotrexate in the treatment of solid tumor leptomeningeal metastases-a Southwest Oncology Group study.  J Neurooncol. 1988;  6 107-112
• 62 Chamberlain M C, Kormanik P. Carcinoma meningitis secondary to non-small cell lung cancer: combined modality therapy.  Arch Neurol. 1998;  55 506-512
• 63 Siegal T. Leptomeningeal metastases: rationale for systemic chemotherapy or what is the role of intra-CSF-chemotherapy?.  J Neurooncol. 1998;  38 151-157
• 64 Giannone L, Greco F A, Hainsworth J D. Combination intraventricular chemotherapy for meningeal neoplasia.  J Clin Oncol. 1986;  4 68-73
• 65 Hitchins R N, Bell D R, Woods R L et al.. A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis.  J Clin Oncol. 1987;  5 1655-1662
• 66 Bleyer W A, Drake J C, Chabner B A. Neurotoxicity and elevated cerebrospinal-fluid methotrexate concentration in meningeal leukemia.  N Engl J Med. 1973;  289 770-773
• 67 Glantz M J, Jaeckle K A, Chamberlain M C et al.. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors.  Clin Cancer Res. 1999;  5 3394-3402
• 68 Glantz M J, LaFollette S, Jaeckle K A et al.. Randomized trial of a slow release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis.  J Clin Oncol. 1999;  17 3110-3116
• 69 Jaeckle K A, Batchelor T, O'Day S J. An open trial of sustained-release cytarabine (Depocyt) for the intrathecal treatment of solid tumor neoplastic meningitis.  J Neurooncol. 2002;  57 231-239
• 70 Siegal T, Pfeffer M R, Steiner I. Antibiotic therapy for infected Ommaya reservoir systems.  Neurosurgery. 1988;  22 97-100
• 71 Kerr J Z, Berg S, Blaney S M. Intrathecal chemotherapy.  Crit Rev Oncol Hematol. 2001;  37 227-236
• 72 Bokstein F, Lossos A, Siegal T. Leptomeningeal metastases from solid tumors: a comparison of two prospective series treated with and without intra-cerebrospinal fluid chemotherapy.  Cancer. 1998;  82 1756-1763
• 73 Glantz M J, Cole B F, Recht L et al.. High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary?.  J Clin Oncol. 1998;  16 1561-1567
• 74 Boogerd W, Dorresteijn L DA, van der Sande J J et al.. Response of leptomeningeal metastases from breast cancer to hormonal therapy.  Neurology. 2000;  55 117-119
• 75 Blaney S M, Poplack D G. New cytotoxic drugs for intrathecal administration.  J Neurooncol. 1998;  38 219-223
• 76 Sampson J H, Archer G E, Villavicencio A T et al.. Treatment of neoplastic meningitis with intrathecal temozolomide.  Clin Cancer Res. 1999;  5 1183-1188
• 77 Herrlinger U, Weller M, Schabet M. New aspects of immunotherapy of leptomeningeal metastasis.  J Neurooncol. 1998;  38 233-239
• 78 Coakham H B, Kemshead J T. Treatment of neoplastic meningitis by targeted radiation using ¹³¹I-radiolabelled monoclonal antibodies.  J Neurooncol. 1998;  38 225-232
• 79 Vrionis F D. Gene therapy of neoplastic meningiosis.  J Neurooncol. 1998;  38 241-244
• 80 Theodore W H, Gendelman S. Meningeal carcinomatosis.  Arch Neurol. 1981;  38 696-699
• 81 Olson M E, Chernik N L, Posner J B. Infiltration of the leptomeninges by systemic cancer. A clinical and pathologic study.  Arch Neurol. 1974;  30 122-137
• 82 Chamberlain M C. Combined modality treatment of leptomeningeal gliomatosis.  Neurosurgery. 2003;  52 324-330
• 83 Chamberlain M C, Kormanik P A, Barba D. Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases.  J Neurosurg. 1997;  87 694-699